Need an investment idea? Check out S2O Stock Screener. It allows to generate a list of stocks of a particular interest in a matter of seconds!

Market Price

125.93 

0.61 0.5%

as of Feb 15 '19

52 Week Range:

113.52 184.00


Stock Analyzer Tutorials

S2O Stock Analyzer - General Info

General Info


type: video (mp4); length: 3:30

Demonstrates how to use Stock Analyzer, shows how to analyze a stock and explains in detail "General Info" section of the Stock Analyzer result page.

S2O Stock Analyzer - Financial Statements

Financial Statements


type: video (mp4); length: 5:10

Explains information presented in the Financial Statements section of the S2O Stock Analyzer: financial statements charts, absolute values and growth rates.

S2O Stock Analyzer - Growth Grade and Financial Ratios

Growth Grade and Financial Ratios


type: video (mp4); length: 5:09

Demonstrates how to use Growth Grade & Financial Ratios section; shows the difference between historical and year-over-year Growth Grade on the real life example.

S2O Stock Analyzer - Value Price

Value Price


type: video (mp4); length: 6:03

Demonstrates how to use Value Price (intrinsic value) and the Graham Number, MOS (margin of safety) and IRT - Investment Recovery Time; explains 3 different projection models used to compute value price - pessimistic, moderate and optimistic.

S2O Stock Analyzer - Price Charts

Price Charts


type: video (mp4); length: 8:34

Demonstrates basic rules of how to read a candlestick chart, long and short term moving averages, stochastic, MACD and relative strength (RS) charts. Explains how bull or bear market condition is computed.

General Info

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology. It markets Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness (EDS) in patients with narcolepsy; Erwinaze to treat acute lymphoblastic leukemia (ALL); Defitelio for the treatment and prevention of severe hepatic veno-occlusive disease, a potentially life-threatening complication of hematopoietic stem cell transplantation; and Prialt, an intrathecally administered infusion of ziconotide for the management of severe chronic pain. The company also develops Solriamfetol (JZP-110), which is in phase III clinical trial for the treatment of excessive sleepiness (ES) in patients with narcolepsy and obstructive sleep apnea, as well as in phase II clinical trial for ES associated with Parkinson's disease; Vyxeos for high-risk acute myeloid leukemia; and JZP-507 and JZP-258 to treat EDS and cataplexy in narcolepsy. In addition, it evaluates deuterated oxybate for narcolepsy; and sells psychiatry and other products. Jazz Pharmaceuticals plc has a strategic collaboration agreement with Codiak BioSciences, Inc. The company is headquartered in Dublin, Ireland.

Financial Statements

The charts below show selected Annual and Quarterly Financial Data.

The purpose of these charts is to discover long and short term change dynamics. When numbers are growing year after year in the annual statements chart, the business become stronger and stronger and this is a good sign.

Quarterly Data Chart can be used to do a short term analysis. It makes sense to pay attention to the quarterly dynamics and do not wait for the next yearly statement. We should be alerted if we see that quarterly numbers are going down.

You can check "Annual Financial Statements" and "Quarterly Financial Statements" sections for exact numbers and growth rates.

Annual Statements

On a charts below the Line shows absolute values and the Bar chart shows Year-Over-Year Growth Rate for selected financial statement item. A consistent GROWTH is generally considered necessary to fund future growth from within a business.
NOTE: Growth Rate is not provided if either the latest period or the year-ago period contains a net loss. (source: WSJ Digest of Earnings)
TIP! move your mouse pointer over bar or a circle on any chart below to see details.

Financial Statements

Income Statement



 

Cash Flow Statement



 

Balance Sheet



 

Liquidity Ratios

Current Ratio


 

Current Ratio measures the ability to meet short term obligations. Generally accepted standard is 2 (current assets should be 2 times or 200% of current liabilities).

Quick Ratio


 

Measures immediate liquidity or the cash available to cover immediate liabilities. A safe margin would be at least 1 (100%).

Financial Leverage


 

Defined as total assets divided by total shareholders' equity. The higher the ratio, the more debt a company uses in its capital structure.

Profitability Ratios

ROA


 

Return on Assets (ROA) measures the income (profit) that is generated by the use of the assets of the business.

ROE


 

Return on Equity (ROE) is a measure of profitability that calculates how many dollars of profit a company generates with each dollar of shareholders equity. ROE is sometimes called "return on net worth."

ROIC


 

The Return on Invested Capital (ROIC) measure gives a sense of how well a company is using its money to generate returns. Some investors use this figure as a final evaluation to determine whether or not to invest in a company.

Annual Statements

Item Name Dec '07 Dec '08 Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17
Equity (BVPS) 2.23
-3.23
-2.33
0.76
3.33
19.32
21.50
22.11
25.50
28.69
40.95
growth rate -100.0% 0.0% 100.0% 338.2% 480.2% 11.3% 2.8% 15.3% 12.5% 42.7%
Earnings BIT -138.83
-184.34
-6.84
32.78
124.98
177.36
372.00
450.02
557.92
640.10
613.84
growth rate 0.0% 0.0% 100.0% 281.3% 41.9% 109.7% 21.0% 24.0% 14.7% -4.1%
Avg.PE -1.40
-1.00
-18.40
23.64
14.47
12.27
36.10
182.89
24.89
23.44
24.37
growth rate 0.0% 0.0% 100.0% -38.8% -15.2% 194.2% 406.6% -86.4% -5.8% 4.0%
ROA -65.77
-113.42
-6.08
26.96
64.21
26.00
10.29
2.09
9.84
9.73
9.83
growth rate 0.0% 0.0% 100.0% 138.2% -59.5% -60.4% -79.7% 370.8% -1.1% 1.0%
ROE -203.50
229.30
9.40
107.30
111.92
43.92
17.90
4.38
22.19
22.83
21.26
growth rate 100.0% -95.9% 1,041.5% 4.3% -60.8% -59.2% -75.5% 406.6% 2.9% -6.9%
ROIC 113.36
25.91
12.64
2.56
11.95
11.83
11.90
growth rate -77.1% -51.2% -79.8% 366.8% -1.0% 0.6%
Cur. Ratio 3.15
0.25
0.62
1.24
3.77
2.88
4.24
4.69
5.55
2.91
3.29
growth rate -92.1% 148.0% 100.0% 204.0% -23.6% 47.2% 10.6% 18.3% -47.6% 13.1%
Quick Ratio 2.94
0.19
0.47
1.12
3.64
2.42
3.73
4.01
5.29
2.56
2.81
growth rate -93.5% 147.4% 138.3% 225.0% -33.5% 54.1% 7.5% 31.9% -51.6% 9.8%
Leverage 3.77
4.44
1.32
1.75
1.73
2.44
2.10
2.56
1.89
growth rate 5.6% -70.3% 32.6% -1.1% 41.0% -13.9% 21.9% -26.2%
Balance Sheet Dec '07 Dec '08 Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17
Acct.Receivable 6.60
12.30
22.10
34.37
75.00
125.00
186.37
209.69
234.24
224.13
growth rate 86.4% 79.7% 55.5% 118.2% 66.7% 49.1% 12.5% 11.7% -4.3%
Acct.Payable 39.91
16.00
21.00
25.13
21.81
22.42
24.37
growth rate -59.9% 31.3% 19.7% -13.2% 2.8% 8.7%
Cur.Assets 44.00
37.00
74.50
199.13
552.00
865.00
1,015.85
1,257.67
748.07
968.28
growth rate -15.9% 101.4% 167.3% 177.2% 56.7% 17.4% 23.8% -40.5% 29.4%
Total Assets 117.50
107.40
135.70
253.57
1,966.00
2,238.00
3,338.96
3,332.61
4,800.23
5,123.67
growth rate -8.6% 26.4% 86.9% 675.3% 13.8% 49.2% -0.2% 44.0% 6.7%
Cash 24.90
15.60
44.80
82.08
387.00
637.00
684.04
988.79
365.96
386.04
growth rate -37.4% 187.2% 83.2% 371.5% 64.6% 7.4% 44.6% -63.0% 5.5%
Inventory 4.30
3.40
5.00
3.91
27.00
29.00
30.04
19.45
34.05
43.25
growth rate -20.9% 47.1% -21.8% 590.7% 7.4% 3.6% -35.2% 75.1% 27.0%
Cur.Liabilities 173.50
59.20
59.90
52.87
192.00
204.00
216.80
226.64
257.41
293.95
growth rate -65.9% 1.2% -11.7% 263.2% 6.3% 6.3% 4.5% 13.6% 14.2%
Liabilities 210.40
180.20
105.20
60.79
845.00
943.00
1,967.75
1,733.97
2,922.89
2,410.58
growth rate -14.4% -41.6% -42.2% 1,290.2% 11.6% 108.7% -11.9% 68.6% -17.5%
LT Debt 75.12
0.00
91.10
24.60
0.00
427.00
544.00
1,333.00
1,150.86
1,993.53
1,540.43
growth rate -100.0% -73.0% -100.0% 27.4% 145.0% -13.7% 73.2% -22.7%
Equity 68.23
-80.39
-72.83
30.60
192.79
1,121.29
1,295.53
1,371.14
1,598.65
1,877.34
2,713.10
growth rate -100.0% 0.0% 100.0% 530.0% 481.6% 15.5% 5.8% 16.6% 17.4% 44.5%
Common Shares 14.00
26.00
30.00
39.00
47.00
60.00
62.00
63.00
63.00
62.00
61.00
growth rate 85.7% 15.4% 30.0% 20.5% 27.7% 3.3% 1.6% 0.0% -1.6% -1.6%
Cash Flow Statement Dec '07 Dec '08 Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17
Capital Expenditures 3.15
1.70
0.10
0.70
1.28
6.00
10.00
36.35
35.96
9.69
28.95
growth rate -46.0% -94.1% 600.0% 82.7% 369.1% 66.7% 263.5% -1.1% -73.1% 198.9%
Cash Dividends 0.00 0.00 0.00 0.00 0.00 0.00
growth rate
Cash From OA -81.09
-130.23
-15.88
58.90
151.60
250.00
288.00
407.61
531.94
592.39
693.09
growth rate 0.0% 0.0% 100.0% 157.4% 64.9% 15.2% 41.5% 30.5% 11.4% 17.0%
FCF per Share -6.09
-6.20
-0.73
1.37
2.75
3.78
4.78
2.08
7.62
5.56
9.32
growth rate 0.0% 0.0% 100.0% 100.7% 37.5% 26.5% -56.5% 266.4% -27.0% 67.6%
Sale Purchase of Stock 16.42
25.00
-105.78
58.49
40.52
24.17
31.82
growth rate 52.3% -100.0% 100.0% -30.7% -40.3% 31.7%
FCF -84.00
-159.00
-22.00
54.00
146.00
227.00
272.00
167.00
496.00
409.00
579.00
growth rate 0.0% 0.0% 100.0% 170.4% 55.5% 19.8% -38.6% 197.0% -17.5% 41.6%
Income Statement Dec '07 Dec '08 Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17
Sales 65.30
67.50
128.40
173.80
272.28
586.00
872.00
1,172.88
1,324.80
1,487.97
1,618.69
growth rate 3.4% 90.2% 35.4% 56.7% 115.2% 48.8% 34.5% 13.0% 12.3% 8.8%
Op.Income -170.40
15.90
57.80
124.98
261.00
372.00
450.02
557.92
640.10
613.84
growth rate 100.0% 263.5% 116.2% 108.8% 42.5% 21.0% 24.0% 14.7% -4.1%
IBT 0.00
0.00
0.00
124.98
177.36
307.95
151.56
435.93
532.07
440.11
growth rate 41.9% 73.6% -50.8% 187.6% 22.1% -17.3%
Net Income -184.30
-6.80
32.80
124.98
261.00
216.00
58.39
329.54
396.83
487.85
growth rate 0.0% 100.0% 281.1% 108.8% -17.2% -73.0% 464.4% 20.4% 22.9%
EPS -10.04
-7.19
-0.23
0.83
2.67
4.79
3.51
0.93
5.23
6.41
7.96
growth rate 0.0% 0.0% 100.0% 221.7% 79.4% -26.7% -73.5% 462.4% 22.6% 24.2%
Gross Profit 44.63
53.60
118.80
160.20
258.34
524.00
774.00
1,065.96
1,222.28
1,382.59
1,508.51
growth rate 20.1% 121.6% 34.9% 61.3% 102.8% 47.7% 37.7% 14.7% 13.1% 9.1%
R&D 70.00
36.60
25.60
14.12
20.48
41.63
85.18
133.45
160.40
196.04
growth rate -47.7% -30.1% -44.8% 45.0% 103.3% 104.6% 56.7% 20.2% 22.2%

Quarterly Statements

Item Name Sep '17 Dec '17 Mar '18 Jun '18 Sep '18
Earnings BIT 161.45
149.21
87.81
196.10
188.78
growth rate -7.6% -41.2% 123.3% -3.7%
Balance Sheet Sep '17 Dec '17 Mar '18 Jun '18 Sep '18
Acct.Receivable 258.62
224.13
281.42
278.44
279.44
growth rate -13.3% 25.6% -1.1% 0.4%
Acct.Payable 29.97
24.37
46.93
31.38
37.37
growth rate -18.7% 92.6% -33.1% 19.1%
Cur.Assets 830.94
968.28
1,126.32
1,306.93
1,464.39
growth rate 16.5% 16.3% 16.0% 12.1%
Total Assets 4,999.02
5,123.67
5,287.13
5,348.97
5,485.79
growth rate 2.5% 3.2% 1.2% 2.6%
Cash 252.62
386.04
453.17
485.08
499.02
growth rate 52.8% 17.4% 7.0% 2.9%
Inventory 41.34
43.25
46.38
46.16
43.44
growth rate 4.6% 7.3% -0.5% -5.9%
Cur.Liabilities 268.18
293.95
375.62
347.95
341.29
growth rate 9.6% 27.8% -7.4% -1.9%
Liabilities 2,529.73
2,410.58
2,500.56
2,479.22
2,458.47
growth rate -4.7% 3.7% -0.9% -0.8%
LT Debt 1,543.82
1,540.43
1,537.04
1,558.31
1,560.58
growth rate -0.2% -0.2% 1.4% 0.2%
Equity 2,469.30
2,713.10
2,786.57
2,869.75
3,027.32
growth rate 9.9% 2.7% 3.0% 5.5%
Common Shares 0.01
0.01
0.01
0.01
0.01
growth rate 0.0% 0.0% 0.0% 0.0%
Cash Flow Statement Sep '17 Dec '17 Mar '18 Jun '18 Sep '18
Capital Expenditures 8.35
8.88
7.15
4.13
3.94
growth rate 6.4% -19.5% -42.2% -4.7%
Cash Dividends
growth rate
Cash From OA 188.90
204.56
162.36
191.62
220.58
growth rate 8.3% -20.6% 18.0% 15.1%
Sale Purchase of Stock 3.72
9.03
10.59
growth rate 142.6% 17.2%
FCF 180.55
195.68
155.21
187.49
216.64
growth rate 8.4% -20.7% 20.8% 15.5%
Income Statement Sep '17 Dec '17 Mar '18 Jun '18 Sep '18
Sales 411.86
436.40
444.61
500.48
469.37
growth rate 6.0% 1.9% 12.6% -6.2%
Op.Income 161.45
149.21
87.81
196.10
188.78
growth rate -7.6% -41.2% 123.3% -3.7%
IBT 64.77
118.55
65.14
128.85
168.66
growth rate 83.1% -45.1% 97.8% 30.9%
Net Income 63.53
232.21
45.99
92.32
149.32
growth rate 265.5% -80.2% 100.7% 61.7%
EPS
growth rate
Gross Profit 380.65
411.15
410.69
465.77
442.80
growth rate 8.0% -0.1% 13.4% -4.9%
R&D 46.86
65.00
62.67
56.13
51.16
growth rate 38.7% -3.6% -10.4% -8.9%

Growth Grade & Financial Ratios

All financial ratios below are calculated based on latest annual statements available and present the most up to date snapshot of a company finances.

Growth Grade

Historical Growth Grade:

A+ (96.46)

YOY Growth Grade:

B (70.33)

Click on buttons above for detailed yearly growth rates.

Market Ratios

Profitability Ratios

Liquidity Ratios

Efficiency Ratios

Value Price

PE and EPS

Historical Current Forward
PE 15.01 14.87 9.09
EPS / Growth 15.1% 8.47 16.5%

Value Price & Investment Recovery Time

Read more about Stock2Own value price in Stock Market: Fundamental Analysis.

Equity Growth Rate: 50.0%

Estimates Pessimistic Moderate Optimistic My Numbers
Rate of Return 15.0%
MOS Price % 50 %
Future EPS Growth 15.1% 27.2% 28.2%
Future PE 9.09 13.04 26.82
Future EPS 34.55 93.81 101.38
Value Price
MOS %
77.65
-38.3%
302.32
140.1%
672.08
433.7%
MOS Price 38.83 151.16 336.04
IRT 7.68 5.94 5.83

Graham Number:

NOTE: The Graham Number applies only to certain types of stocks in combination with a number of other criteria.

Read more about Graham Number in Stock Market: Fundamental Analysis.

Price Chart

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.

Risk / Reward Ratios

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.